These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

440 related items for PubMed ID: 25249260

  • 1. Different patterns in the prognostic value of age for breast cancer-specific mortality depending on hormone receptor status: a SEER population-based analysis.
    Liu YR, Jiang YZ, Yu KD, Shao ZM.
    Ann Surg Oncol; 2015 Apr; 22(4):1102-10. PubMed ID: 25249260
    [Abstract] [Full Text] [Related]

  • 2. Hormone receptor-negative breast cancer: undertreatment of patients over 80.
    Weiss A, Noorbakhsh A, Tokin C, Chang D, Blair SL.
    Ann Surg Oncol; 2013 Oct; 20(10):3274-8. PubMed ID: 23838924
    [Abstract] [Full Text] [Related]

  • 3. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.
    Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI.
    Cancer; 2005 Jun 01; 103(11):2241-51. PubMed ID: 15844176
    [Abstract] [Full Text] [Related]

  • 4. Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study.
    Zheng YZ, Wang L, Hu X, Shao ZM.
    Oncotarget; 2015 Sep 08; 6(26):22985-95. PubMed ID: 26036636
    [Abstract] [Full Text] [Related]

  • 5. Hazard of breast cancer-specific mortality among women with estrogen receptor-positive breast cancer after five years from diagnosis: implication for extended endocrine therapy.
    Yu KD, Wu J, Shen ZZ, Shao ZM.
    J Clin Endocrinol Metab; 2012 Dec 08; 97(12):E2201-9. PubMed ID: 22993034
    [Abstract] [Full Text] [Related]

  • 6. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J, Xia Y, Wu Q, Zhu S, Chen C, Yang W, Wei W, Sun S.
    Oncotarget; 2017 Jul 25; 8(30):49370-49379. PubMed ID: 28472761
    [Abstract] [Full Text] [Related]

  • 7. The Prognostic Impact of Age at Diagnosis Upon Breast Cancer of Different Immunohistochemical Subtypes: A Surveillance, Epidemiology, and End Results (SEER) Population-Based Analysis.
    Cai S, Zuo W, Lu X, Gou Z, Zhou Y, Liu P, Pan Y, Chen S.
    Front Oncol; 2020 Jul 25; 10():1729. PubMed ID: 33072554
    [Abstract] [Full Text] [Related]

  • 8. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma.
    Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, Rouzier R, Broglio KR, Hortobagyi GN, Valero V.
    J Clin Oncol; 2007 Nov 01; 25(31):4952-60. PubMed ID: 17971593
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Is conservative surgery a good option for patients with "triple negative" breast cancer?
    Martinez-Ramos D, Escrig-Sos J, Torrella-Ramos A, Alcalde-Sanchez M, Salvador-Sanchis JL.
    Breast; 2012 Jun 01; 21(3):401-5. PubMed ID: 22579462
    [Abstract] [Full Text] [Related]

  • 12. Hormone receptor status may impact the survival benefit of surgery in stage iv breast cancer: a population-based study.
    Tan Y, Li X, Chen H, Hu Y, Jiang M, Fu J, Yuan Y, Ding K.
    Oncotarget; 2016 Oct 25; 7(43):70991-71000. PubMed ID: 27542240
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey.
    Kuzhan A, Adli M, Eryigit Alkis H, Caglayan D.
    J BUON; 2013 Oct 25; 18(3):619-22. PubMed ID: 24065473
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adjuvant chemotherapy could not bring survival benefit to HR-positive, HER2-negative, pT1b-c/N0-1/M0 invasive lobular carcinoma of the breast: a propensity score matching study based on SEER database.
    Hu G, Hu G, Zhang C, Lin X, Shan M, Yu Y, Lu Y, Niu R, Ye H, Wang C, Xu C.
    BMC Cancer; 2020 Feb 21; 20(1):136. PubMed ID: 32085753
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The impact of age on outcomes of breast cancer in different hormone receptor and HER2 groups.
    Zheng H, Ge C, Lin H, Zhou S, Tang W, Wang Q, Zhang X, Jin X, Xu X, Du J, Fu J.
    PLoS One; 2023 Feb 21; 18(1):e0280474. PubMed ID: 36652446
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.